



August 14, 2024

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Perseus Proteomics Inc. (The Company) announces that the non-operating income, non-operating expenses, and extraordinary losses were recorded in the first three months of the fiscal year 2025/03. The details are as follows:

1. Non-operating income

The Company has recorded foreign exchange gains of 10,017 thousand yen as non-operating income.

2. Non-operating expenses

The Company has recorded share issuance costs of 432 thousand yen and taxes and dues of 2,517 thousand yen associated with capital increase through exercise of share acquisition rights as non-operating expenses respectively.

3. Extraordinary losses

The Company has recorded impairment loss of 3,880 thousand yen for its non-current assets in accordance with the Accounting Standard for Impairment of Fixed Assets as extraordinary losses,.

4. Impact on financial results

The above items have been fully reflected in the “Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2025” announced today.

END